Received Sep 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
drug dose administration interval too long; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received first dose on 03-JAN-2025). In AUG-2025, the patient received the 2nd dose of Shingrix. In AUG-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: drug dose administration interval too long). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 29-AUG-2025 The reporter stated that the patient got Shingrix shot 1 on 03-Jan-2025 and Shingrix shot 2 on an unspecified date last week (August 2025). Patient was told by physician that he could get the second dose between 28-FEB-2025 and 30-AUG-2025. The patient received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccinations schedule.